UA111599C2 - Композиція каспофунгіну - Google Patents
Композиція каспофунгінуInfo
- Publication number
- UA111599C2 UA111599C2 UAA201304481A UAA201304481A UA111599C2 UA 111599 C2 UA111599 C2 UA 111599C2 UA A201304481 A UAA201304481 A UA A201304481A UA A201304481 A UAA201304481 A UA A201304481A UA 111599 C2 UA111599 C2 UA 111599C2
- Authority
- UA
- Ukraine
- Prior art keywords
- composition
- preparation
- lyophilized
- pharmaceutically acceptable
- relates
- Prior art date
Links
- 108010020326 Caspofungin Proteins 0.000 title 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical group C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 title 1
- 229960003034 caspofungin Drugs 0.000 title 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000008362 succinate buffer Substances 0.000 abstract 1
- OGUJBRYAAJYXQP-IJFZAWIJSA-N vuw370o5qe Chemical class CC(O)=O.CC(O)=O.C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 OGUJBRYAAJYXQP-IJFZAWIJSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Винахід належить до композиції, способу її одержання та застосування, що містить фармацевтично ефективну кількість ацетатної солі каспофунгіну, фармацевтично прийнятну кількість одного або більше ніж одного фармацевтично прийнятного ексципієнта, ефективного для утворення ліофілізованої таблетки та фармацевтично ефективну кількість буферного агента, що є сукцинатом. Також винахід належить до ліофілізованого препарату парентерального введення для лікування або попередження грибкової інфекції, що складається з заявленої композиції та набору, що містить вказаний ліофілізований препарат.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38433310P | 2010-09-20 | 2010-09-20 | |
| PCT/EP2011/066202 WO2012038371A1 (en) | 2010-09-20 | 2011-09-19 | Caspofungin composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA111599C2 true UA111599C2 (uk) | 2016-05-25 |
Family
ID=44677877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201304481A UA111599C2 (uk) | 2010-09-20 | 2011-09-19 | Композиція каспофунгіну |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20120101030A1 (uk) |
| EP (1) | EP2618814B1 (uk) |
| JP (1) | JP5914486B2 (uk) |
| KR (1) | KR20130136466A (uk) |
| CN (1) | CN103118663A (uk) |
| AU (1) | AU2011304408B2 (uk) |
| CA (1) | CA2810112A1 (uk) |
| DK (1) | DK2618814T3 (uk) |
| ES (1) | ES2593727T3 (uk) |
| HR (1) | HRP20161236T1 (uk) |
| HU (1) | HUE030464T2 (uk) |
| IL (1) | IL225339A0 (uk) |
| MX (1) | MX2013003045A (uk) |
| PL (1) | PL2618814T3 (uk) |
| PT (1) | PT2618814T (uk) |
| RS (1) | RS55216B1 (uk) |
| RU (1) | RU2013114993A (uk) |
| UA (1) | UA111599C2 (uk) |
| WO (1) | WO2012038371A1 (uk) |
| ZA (1) | ZA201302113B (uk) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103212059A (zh) * | 2012-01-18 | 2013-07-24 | 江苏恒瑞医药股份有限公司 | 含有抗真菌药物和乳酸盐缓冲液的组合物 |
| CN103212058A (zh) * | 2012-01-18 | 2013-07-24 | 江苏恒瑞医药股份有限公司 | 含有抗真菌药物和乳酸盐缓冲剂的组合物 |
| US9636407B2 (en) * | 2012-11-20 | 2017-05-02 | Fresenius Kabi Usa, Llc | Caspofungin acetate formulations |
| CN103142997A (zh) * | 2013-03-13 | 2013-06-12 | 浙江海正药业股份有限公司 | 含有抗真菌剂和琥珀酸盐缓冲液的药物组合物 |
| KR20140123782A (ko) * | 2013-04-15 | 2014-10-23 | 에스케이케미칼주식회사 | 카스포펀진 및 완충제를 포함하는 안정성이 개선된 약학적 조성물 |
| CN104116716A (zh) * | 2013-04-25 | 2014-10-29 | 四川海思科制药有限公司 | 一种含卡泊芬净的冻干粉针剂药物组合物 |
| EP3054924B1 (en) * | 2013-10-07 | 2020-11-25 | Galenicum Health S.L.U. | Stable pharmaceutical formulations of caspofungin |
| GR1008818B (el) * | 2015-05-22 | 2016-08-01 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου |
| CN108760937B (zh) * | 2018-07-27 | 2020-12-29 | 杭州华东医药集团新药研究院有限公司 | 醋酸卡泊芬净中残留乙二胺的测定及其应用 |
| CN109758426B (zh) * | 2019-01-24 | 2021-04-27 | 四川制药制剂有限公司 | 一种注射用醋酸卡泊芬净药物组合物及其制备方法 |
| CN110859950B (zh) * | 2019-11-25 | 2021-08-10 | 武汉大学 | 一种用于白念珠菌棘白菌素类药物耐药菌的药物组合物及其应用 |
| EP4364566A1 (en) * | 2022-11-04 | 2024-05-08 | B. Braun Melsungen AG | Anti-fungal composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991015121A1 (en) * | 1990-03-30 | 1991-10-17 | Smithkline Beecham Corporation | Method for treating fungal infection |
| JP2930823B2 (ja) | 1991-12-11 | 1999-08-09 | 株式会社東芝 | Ｘ線ｃｔスキャナ用検出器及びｘ線検出装置用シンチレータチャネルセパレータ |
| US5378804A (en) | 1993-03-16 | 1995-01-03 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
| US5952300A (en) | 1996-04-19 | 1999-09-14 | Merck & Co., Inc. | Antifungal compositions |
| US20080046580A1 (en) | 2006-06-29 | 2008-02-21 | Nokia Corporation | Account creation system and call processing system |
| CN101516387B (zh) * | 2006-07-26 | 2014-06-04 | 桑多斯股份公司 | 卡泊芬净制剂 |
| EP2049142B2 (en) * | 2006-07-26 | 2016-01-20 | Sandoz AG | Caspofungin formulations |
| WO2009002481A1 (en) | 2007-06-26 | 2008-12-31 | Merck & Co., Inc. | Lyophilized anti-fungal composition |
| EP2285236A1 (en) * | 2008-05-30 | 2011-02-23 | DSM IP Assets B.V. | Use of succinic acid |
| US20090324635A1 (en) | 2008-06-25 | 2009-12-31 | Ferenc Korodi | Caspofungin free of caspofungin impurity A |
-
2011
- 2011-09-19 AU AU2011304408A patent/AU2011304408B2/en not_active Ceased
- 2011-09-19 HR HRP20161236TT patent/HRP20161236T1/hr unknown
- 2011-09-19 CN CN2011800451119A patent/CN103118663A/zh active Pending
- 2011-09-19 CA CA2810112A patent/CA2810112A1/en not_active Abandoned
- 2011-09-19 EP EP11761049.3A patent/EP2618814B1/en active Active
- 2011-09-19 DK DK11761049.3T patent/DK2618814T3/en active
- 2011-09-19 JP JP2013528699A patent/JP5914486B2/ja not_active Expired - Fee Related
- 2011-09-19 MX MX2013003045A patent/MX2013003045A/es active IP Right Grant
- 2011-09-19 UA UAA201304481A patent/UA111599C2/uk unknown
- 2011-09-19 HU HUE11761049A patent/HUE030464T2/en unknown
- 2011-09-19 RS RS20160810A patent/RS55216B1/sr unknown
- 2011-09-19 ES ES11761049.3T patent/ES2593727T3/es active Active
- 2011-09-19 WO PCT/EP2011/066202 patent/WO2012038371A1/en not_active Ceased
- 2011-09-19 RU RU2013114993/15A patent/RU2013114993A/ru not_active Application Discontinuation
- 2011-09-19 KR KR1020137010070A patent/KR20130136466A/ko not_active Ceased
- 2011-09-19 PL PL11761049T patent/PL2618814T3/pl unknown
- 2011-09-19 PT PT117610493T patent/PT2618814T/pt unknown
- 2011-09-20 US US13/237,193 patent/US20120101030A1/en not_active Abandoned
-
2013
- 2013-03-19 IL IL225339A patent/IL225339A0/en unknown
- 2013-03-20 ZA ZA2013/02113A patent/ZA201302113B/en unknown
-
2014
- 2014-11-19 US US14/547,742 patent/US9393307B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20161236T1 (hr) | 2016-11-18 |
| AU2011304408A1 (en) | 2013-03-28 |
| US20150072923A1 (en) | 2015-03-12 |
| HUE030464T2 (en) | 2017-05-29 |
| EP2618814A1 (en) | 2013-07-31 |
| MX2013003045A (es) | 2013-06-24 |
| ES2593727T3 (es) | 2016-12-12 |
| US20120101030A1 (en) | 2012-04-26 |
| PT2618814T (pt) | 2016-10-06 |
| CA2810112A1 (en) | 2012-03-29 |
| WO2012038371A1 (en) | 2012-03-29 |
| ZA201302113B (en) | 2014-05-28 |
| RU2013114993A (ru) | 2014-10-27 |
| JP5914486B2 (ja) | 2016-05-11 |
| RS55216B1 (sr) | 2017-02-28 |
| CN103118663A (zh) | 2013-05-22 |
| EP2618814B1 (en) | 2016-07-27 |
| KR20130136466A (ko) | 2013-12-12 |
| DK2618814T3 (en) | 2016-10-10 |
| IL225339A0 (en) | 2013-06-27 |
| AU2011304408B2 (en) | 2015-01-15 |
| US9393307B2 (en) | 2016-07-19 |
| PL2618814T3 (pl) | 2017-01-31 |
| JP2013537212A (ja) | 2013-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA111599C2 (uk) | Композиція каспофунгіну | |
| WO2011099832A3 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
| EP4606434A3 (en) | Deuterated derivatives of ruxolitinib | |
| WO2011086093A3 (en) | Pharmaceutical compositions for oral administration of insulin peptides | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| NZ703064A (en) | Inhibitors of hepatitis c virus | |
| NZ708016A (en) | Lyophilized preparations of melphalan flufenamide | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| CL2012001080A1 (es) | Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida. | |
| MX348823B (es) | Formulaciones estables de linaclotida. | |
| IN2013MU03583A (uk) | ||
| MX350746B (es) | Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral. | |
| MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
| MX2013004190A (es) | Composiciones y metodos para el tratamiento de la hipertension pulmonar. | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| NZ600695A (en) | Combination composition, comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency | |
| MX2016007682A (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
| WO2013096335A8 (en) | ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT | |
| MY193996A (en) | Tripeptide compound, preparation method therefor, and application thereof | |
| EP2611799A4 (en) | PHARMACEUTICAL COMPOSITIONS OF LINEZOLID | |
| DOP2013000206A (es) | Inhibidores de la peptido desformilasa | |
| MX370957B (es) | Compuesto de la familia de la avermectina o de la familia de la milbemicina para el tratamiento y/o la prevención de la dermatitis atópica. | |
| EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина |